The company’s technology platform allows Procarta to rapidly design proprietary Narrow- or Broad-spectrum antibacterials to treat extant and emerging infections. Procarta is seeking partners and investment to develop lead compounds across multiple indications in order to realise the full potential of its capabilities.
If you’d like to discuss more, contact:
Dr. Martin Stocks
Tel: 01603 456500